The Targeted SMAC Mimetic SW IV-134 is a strong enhancer of standard chemotherapy in pancreatic cancer

BACKGROUND: Pancreatic cancer is a lethal malignancy that frequently acquires resistance to conventional chemotherapies often associated with overexpression of inhibitors of apoptosis proteins (IAPs). We have recently described a novel means to deliver second mitochondria-derived activator of caspas...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Exp Clin Cancer Res
Main Authors: Hashim, Yassar M., Vangveravong, Suwanna, Sankpal, Narendra V., Binder, Pratibha S., Liu, Jingxia, Goedegebuure, S. Peter, Mach, Robert H., Spitzer, Dirk, Hawkins, William G.
Formato: Artigo
Idioma:Inglês
Publicado em: BioMed Central 2017
Assuntos:
Research
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5240213/
https://ncbi.nlm.nih.gov/pubmed/28095907
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13046-016-0470-4
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados